Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome: A multicenter study from the AIDA Network PFAPA syndrome registry

Imagem de Miniatura
Arquivos
art_TORRE_Preliminary_data_revealing_efficacy_of_Streptococcus_salivarius_K12_.PDF (864.77 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
TORRE, Francesco La
SOTA, Jurgen
INSALACO, Antonella
CONTI, Giovanni
GIUDICE, Emanuela Del
LUBRANO, Riccardo
BREDA, Luciana
MAGGIO, Maria Cristina
CIVINO, Adele
MASTRORILLI, Violetta
Citação
FRONTIERS IN MEDICINE, v.10, article ID 1105605, 7p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
ObjectiveTo evaluate the potential role of Streptococcus salivarius K12 (SSK12) in controlling febrile flares in patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome. Further aims were to assess the impact of SSK12 on (i) flare duration, (ii) variation in the degree of the highest body temperature during flares, (iii) steroid-sparing effect, and (iv) change of PFAPA accompanying symptoms before and after SSK12 introduction. Patients and methodsThe medical charts from 85 pediatric patients with PFAPA syndrome (49 males and 36 females) enrolled in the AIDA registry and treated with SSK12 for a median period of 6.00 +/- 7.00 months in the period between September 2017 and May 2022 were examined. Children recruited had a median time of disease duration of 19.00 +/- 28.00 months. ResultsThe number of febrile flares significantly decreased comparing the 12 months before [median (IQR), 13.00 (6.00)] and after SSK12 initiation [median (IQR), 5.50 (8.00), p < 0.001]. The duration of fever was significantly reduced from 4.00 (2.00) days to 2.00 (2.00) days [p < 0.001]. Similarly, the highest temperature in degrees C was found significantly lower in the last follow-up assessment [median (IQR), 39.00 (1.00)] compared to the period prior to SSK12 start [median (IQR), 40.00 (1.00), p < 0.001]. Steroid load (mg/year) of betamethasone (or any equivalent steroid) significantly decreased between 12 months before treatment with SSK12 [median (IQR), 5.00 (8.00) mg/year] and the last follow-up visit [median (IQR), 2.00 (4.00) mg/year, p < 0.001]. The number of patients experiencing symptoms including pharyngitis/tonsillitis (p < 0.001), oral aphthae (p < 0.001) and cervical lymphadenopathy (p < 0.001) significantly decreased following SSK12. ConclusionSSK12 prophylaxis given for at least 6.00 months was found to reduce febrile flares of PFAPA syndrome: in particular, it halved the total number per year of fever flares, shortened the duration of the single febrile episode, lowered body temperature by 1 degrees C in the febrile flare, provided a steroid-sparing effect, and significantly reduced the accompanying symptoms related to the syndrome.
Palavras-chave
PFAPA syndrome, autoinflammatory disease, International Registry, Streptococcus salivarius K12, probiotic, tonsillitis, prophylaxis
URI
https://observatorio.fm.usp.br/handle/OPI/53158
Referências
  1. Batu ED, 2022, RHEUMATOL INT, V42, P1207, DOI 10.1007/s00296-021-05084-y
  2. Della Casa F, 2022, FRONT PEDIATR, V10, DOI 10.3389/fped.2022.930305
  3. Di Pierro F., 2016, ALTERN INTEGR MED, V5, DOI 10.4172/2327-5162.1000222
  4. Di Pierro F, 2014, DRUG HEALTHC PATIENT, V6, P15, DOI 10.2147/DHPS.S59665
  5. Di Pierro F, 2012, INT J GEN MED, V5, P991, DOI 10.2147/IJGM.S38859
  6. Feder HM, 2010, ACTA PAEDIATR, V99, P178, DOI 10.1111/j.1651-2227.2009.01554.x
  7. Gaggiano C, 2019, CLIN RHEUMATOL, V38, P11, DOI 10.1007/s10067-018-4361-2
  8. Gattorno M, 2019, ANN RHEUM DIS, V78, P1025, DOI 10.1136/annrheumdis-2019-215048
  9. Gentileschi S, 2017, EXPERT OPIN ORPHAN D, V5, P165, DOI 10.1080/21678707.2017.1279049
  10. Gozen ED, 2022, RHEUMATOL INT, DOI 10.1007/s00296-022-05210-4
  11. Gregori G, 2016, THER CLIN RISK MANAG, V12, P87, DOI 10.2147/TCRM.S96134
  12. Grimwood C, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0878-3
  13. Guo HY, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.900448
  14. Hyink O, 2007, APPL ENVIRON MICROB, V73, P1107, DOI 10.1128/AEM.02265-06
  15. MARSHALL GS, 1987, J PEDIATR-US, V110, P43, DOI 10.1016/S0022-3476(87)80285-8
  16. Raeeskarami SR, 2022, PEDIATR RHEUMATOL, V20, DOI 10.1186/s12969-022-00733-3
  17. Rigante D, 2020, INT J PEDIATR OTORHI, V130, DOI 10.1016/j.ijporl.2019.109830
  18. Rigante D, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/485103
  19. Sangiorgi E, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11142231
  20. Thomas KT, 1999, J PEDIATR-US, V135, P15, DOI 10.1016/S0022-3476(99)70321-5
  21. Vanoni F, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969-016-0101-9
  22. Wang Alicia, 2021, World J Otorhinolaryngol Head Neck Surg, V7, P166, DOI 10.1016/j.wjorl.2021.05.004
  23. Wescombe PA, 2012, FUTURE MICROBIOL, V7, P1355, DOI [10.2217/fmb.12.113, 10.2217/FMB.12.113]

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17